https://www.yiliao.com/index.php?action=history&feed=atom&title=Idecabtagene_vicleucel
Idecabtagene vicleucel - 版本历史
2026-04-18T15:50:36Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Idecabtagene_vicleucel&diff=314241&oldid=prev
223.160.138.80：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-13T08:30:08Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[Idecabtagene vicleucel]]</strong>（简称<strong>[[Ide-cel]]</strong>），商品名为<strong>[[Abecma]]</strong>，是一种针对<strong>[[B细胞成熟抗原]]</strong>（<strong>[[BCMA]]</strong>）的自体<strong>[[CAR-T]]</strong>（嵌合抗原受体T细胞）疗法。作为全球首个获批用于治疗<strong>[[多发性骨髓瘤]]</strong>的<strong>[[CAR-T]]</strong>产品，它通过基因工程手段使患者自身的<strong>[[T细胞]]</strong>表达能识别<strong>[[BCMA]]</strong>的嵌合抗原受体。<strong>[[Ide-cel]]</strong>包含一个抗<strong>[[BCMA]]</strong>的单链抗体片段（scFv）、<strong>[[4-1BB]]</strong>共刺激结构域以及<strong>[[CD3ζ]]</strong>激活结构域。该疗法主要用于治疗既往接受过包括免疫调节剂、蛋白酶体抑制剂和抗<strong>[[CD38]]</strong>单抗在内的至少三线治疗失败的复发或难治性<strong>[[多发性骨髓瘤]]</strong>（RRMM）成年患者，开创了骨髓瘤<strong>[[免疫治疗]]</strong>的新纪元。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Idecabtagene vicleucel</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Abecma·BCMA靶向CAR-T·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Cell Therapy:Genetically Modified Autologous T-cells</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：<strong>[[BCMA]]</strong>(TNFRSF17)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;"><strong>[[Entrez]]</strong>ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">608(<strong>[[BCMA]]</strong>)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">自体细胞免疫疗法</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">共刺激域</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[4-1BB]]</strong>(CD137)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[BMS]]</strong>/<strong>[[2seventybio]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">静脉输注</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">审批状态</th><br />
<td style="padding: 12px; color: #16a34a;"><strong>[[FDA]]</strong>/<strong>[[EMA]]</strong>已上市</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">作用机制：重定向T细胞清除骨髓瘤</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
<strong>[[Idecabtagene vicleucel]]</strong>通过将患者的<strong>[[T细胞]]</strong>转化为精准打击肿瘤的“活药”，其药理过程包括：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">靶向识别：CAR结构中的scFv片段能够特异性结合浆细胞表面的<strong>[[BCMA]]</strong>抗原。<strong>[[BCMA]]</strong>在正常组织中几乎不表达，但在恶性浆细胞中广泛存在，确保了治疗的靶向性。</li><br />
<li style="margin-bottom: 12px;">级联激活：一旦结合靶点，<strong>[[CD3ζ]]</strong>激活域启动第一信号，随后<strong>[[4-1BB]]</strong>结构域提供强力的共刺激信号，诱导<strong>[[CAR-T]]</strong>细胞在体内迅速扩增并活化。</li><br />
<li style="margin-bottom: 12px;">细胞毒杀伤：活化的<strong>[[CAR-T]]</strong>细胞释放<strong>[[穿孔素]]</strong>和<strong>[[颗粒酶]]</strong>，诱导肿瘤细胞<strong>[[凋亡]]</strong>，并分泌细胞因子（如干扰素-γ）增强局部抗肿瘤免疫应答。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价：KarMMa关键研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">评价指标</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">KarMMa临床数据</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床解读</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">客观缓解率(ORR)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>73.0%</strong></td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在多线耐药的末线患者中表现出极高的响应比例。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">完全缓解率(CR+)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">33.0%</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">约三分之一的患者达到了微小残留病(MRD)阴性的深度缓解。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">中位PFS</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">8.8个月</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在450×10^6剂量组中，中位PFS可进一步提升。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">安全性特征</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;" colspan="2;">CRS发生率为84%（多为1-2级），ICANS发生率为18%，需严格住院监控。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：个性化制备与毒性风险管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
<strong>[[Idecabtagene vicleucel]]</strong>作为一种复杂的活细胞产品，其临床流程强调全程质量管控：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">单采与回输：患者需经历白细胞单采、体外<strong>[[慢病毒]]</strong>转导扩增，以及回输前的<strong>[[清淋化疗]]</strong>（环磷酰胺+氟达拉滨），以优化体内细胞生存环境。</li><br />
<li style="margin-bottom: 12px;"><strong>[[细胞因子释放综合征]]</strong>(CRS)管理：治疗后需密切监测发热、低血压。<strong>[[托珠单抗]]</strong>是管理中重度CRS的首选解救方案。</li><br />
<li style="margin-bottom: 12px;">神经毒性预警：监测<strong>[[ICANS]]</strong>症状，包括书写能力下降、意识模糊等。早期使用皮质类固醇对控制进展至关重要。</li><br />
<li style="margin-bottom: 12px;">长期随访：鉴于<strong>[[CAR-T]]</strong>的特性，需警惕长期<strong>[[血细胞减少]]</strong>及继发性感染，建议至少进行15年的安全性随访。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[BCMA]]</strong>：骨髓瘤细胞特异性标志物，是CAR-T与双抗竞争的核心靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Ciltacabtagene autoleucel]]</strong>(Carvykti)：另一款获批的BCMA-CAR-T，是Ide-cel的主要竞争对手。</li><br />
<li style="margin-bottom: 8px;"><strong>[[清淋化疗]]</strong>：回输前清除体内内源性淋巴细胞，为CAR-T扩增腾挪“空间”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[BMS]]</strong>：百时美施贵宝，该药的主要全球商业化实体。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Munshi NC, et al. (2021).</strong> <em>Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究证实了Ide-cel在高度难治人群中的突破性疗效，改变了晚期骨髓瘤的治疗范式。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Alsina M, et al. (2024).</strong> <em>Real-world outcomes of Idecabtagene Vicleucel: A three-year follow-up.</em> <strong>[[Blood Advances]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：总结了该疗法在临床实践中的长期生存数据，强调了早期干预毒性的重要性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
Idecabtagene vicleucel (Ide-cel) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[BCMA]]</strong>•<strong>[[CD3]]</strong>•<strong>[[4-1BB]]</strong>•<strong>[[CD38]]</strong>•<strong>[[GPRC5D]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类/竞争</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[西达基奥仑赛]]</strong>•<strong>[[特立妥珠单抗]]</strong>•<strong>[[埃兰妥单抗]]</strong>•<strong>[[塔奎妥单抗]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[BMS]]</strong>•<strong>[[2seventybio]]</strong>•<strong>[[FDA]]</strong>•<strong>[[NCCN]]</strong>•<strong>[[ASCO]]</strong></td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[一线高危患者探索]]</strong>•<strong>[[联合达雷妥尤单抗]]</strong>•<strong>[[二代双靶向CAR-T开发]]</strong>•<strong>[[克服靶点丢失耐药机制]]</strong></td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.80